<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561560</url>
  </required_header>
  <id_info>
    <org_study_id>P-347-C-019</org_study_id>
    <nct_id>NCT01561560</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses</brief_title>
  <official_title>Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this crossover study was to evaluate the end-of-day comfort of two
      commercially available, daily disposable, silicone hydrogel contact lenses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End-of-day Comfort</measure>
    <time_frame>Week 2</time_frame>
    <description>End-of-day comfort was interpreted and reported by the participant on a questionnaire as a single, retrospective measurement of two weeks of wear. Participants were asked, &quot;Please rate the study lenses you have been wearing the in the following area: End-of-day comfort&quot; and recorded their response on a continuous 1-10 Likert scale (1=poor and 10=excellent).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>DAILIES TOTAL1, then TRUEYE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRUEYE, then DAILIES TOTAL1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Delefilcon A contact lenses</intervention_name>
    <description>CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two</description>
    <arm_group_label>DAILIES TOTAL1, then TRUEYE</arm_group_label>
    <arm_group_label>TRUEYE, then DAILIES TOTAL1</arm_group_label>
    <other_name>DAILIES TOTAL1®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Narafilcon A contact lenses</intervention_name>
    <description>CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two</description>
    <arm_group_label>DAILIES TOTAL1, then TRUEYE</arm_group_label>
    <arm_group_label>TRUEYE, then DAILIES TOTAL1</arm_group_label>
    <other_name>1-DAY ACUVUE® TRUEYE™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign written Informed Consent Document.

          -  Currently wearing soft contact lenses in both eyes and identified as symptomatic based
             on questionnaire responses.

          -  Currently wearing either daily disposable contact lenses or weekly/monthly replacement
             contact lenses.

          -  Able to achieve visual acuity of at least 6/7.5 in each eye with study lenses in the
             available parameters.

          -  Willing to wear study lenses for at least eight hours per day and at least five days
             per week.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Has not worn contact lenses before.

          -  Currently wearing DAILIES TOTAL1 or 1-DAY ACUVUE TRUEYE contact lenses.

          -  Any systemic or ocular disease or disorder that would negatively affect the conduct or
             outcome of the study.

          -  Ocular surgery/trauma within the last six months.

          -  Topical ocular or systemic use of antibiotics within seven days of enrollment.

          -  Pregnant or nursing women.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camille Girault</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2012</study_first_posted>
  <results_first_submitted>November 19, 2013</results_first_submitted>
  <results_first_submitted_qc>November 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 7, 2014</results_first_posted>
  <last_update_submitted>November 19, 2013</last_update_submitted>
  <last_update_submitted_qc>November 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DAILIES TOTAL1</keyword>
  <keyword>contact lenses</keyword>
  <keyword>myopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from two study centers in Finland, three study centers in German, and three study centers in the UK.</recruitment_details>
      <pre_assignment_details>Of the 123 participants enrolled, two were excluded prior to randomization. This reporting group includes all participants enrolled and exposed to Test Article (121).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DAILIES TOTAL1, Then TRUEYE</title>
          <description>Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.</description>
        </group>
        <group group_id="P2">
          <title>TRUEYE, Then DAILIES TOTAL1</title>
          <description>Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Two Weeks of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Time/job conflict</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Two Weeks of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants enrolled and exposed to Test Article</population>
      <group_list>
        <group group_id="B1">
          <title>OVERALL</title>
          <description>Delefilcon A contact lenses and narafilcon A contact lenses worn in randomized order. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.0" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>End-of-day Comfort</title>
        <description>End-of-day comfort was interpreted and reported by the participant on a questionnaire as a single, retrospective measurement of two weeks of wear. Participants were asked, &quot;Please rate the study lenses you have been wearing the in the following area: End-of-day comfort&quot; and recorded their response on a continuous 1-10 Likert scale (1=poor and 10=excellent).</description>
        <time_frame>Week 2</time_frame>
        <population>This reporting group includes all participants who finished the study, minus any major protocol deviations as determined by masked review.</population>
        <group_list>
          <group group_id="O1">
            <title>DAILIES TOTAL1</title>
            <description>Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for two weeks</description>
          </group>
          <group group_id="O2">
            <title>TRUEYE</title>
            <description>Narafilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>End-of-day Comfort</title>
          <description>End-of-day comfort was interpreted and reported by the participant on a questionnaire as a single, retrospective measurement of two weeks of wear. Participants were asked, &quot;Please rate the study lenses you have been wearing the in the following area: End-of-day comfort&quot; and recorded their response on a continuous 1-10 Likert scale (1=poor and 10=excellent).</description>
          <population>This reporting group includes all participants who finished the study, minus any major protocol deviations as determined by masked review.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="1.91"/>
                    <measurement group_id="O2" value="6.6" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the study. The safety population includes all participants enrolled and exposed to Test Article.</time_frame>
      <desc>An adverse event was defined as an event that caused, or had the potential to cause, unexpected or unwanted effects involving the safety of device users (including patients) or other persons.</desc>
      <group_list>
        <group group_id="E1">
          <title>DAILIES TOTAL1</title>
          <description>Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for two weeks</description>
        </group>
        <group group_id="E2">
          <title>TRUEYE</title>
          <description>Narafilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for two weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study data should not be disclosed to any third party for a period of three years after the termination of the study without prior written consent.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jami Kern, PhD</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

